The sale is pre-planned under a 10b5-1 arrangement, reducing immediate negative signal; however, traders should monitor for follow-through sales and assess whether additional insider selling follows, which could indicate broader sentiment.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 16 $67.07entry
- T+1 · 7mo ago +2.76%α +1.54% · $68.92
- T+5 · 7mo ago +1.00%α +0.02% · $67.74
- T+20 · 6mo ago −5.80%α −11.62% · $63.18
- T+60 · 4mo ago +26.08%α +19.03% · $84.56
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Joana Goncalves, an officer of Oruka Therapeutics, filed a Form 144 to notify intent to sell up to 21,000 shares of common stock received from exercised stock options. The sale is part of a pre-arranged 10b5-1 plan and follows prior sales in February and March 2026.
Key Facts
- Joana Goncalves, an officer at Oruka Therapeutics, filed Form 144 for the proposed sale of 21,000 shares.
- The shares were acquired through the exercise of stock options and are being sold under a 10b5-1 plan.
- Prior sales occurred on February 17, 2026 (7,000 shares) and March 16, 2026 (7,641 shares), totaling over 14,000 shares sold or proposed for sale recently.
- The filing date is April 15, 2026, with the underlying options exercised on that date.
Financial Impact
Approximately $1.41 million based on the reported value of $1,408,260 for 21,000 shares, or about $67.06 per share.
Risk Factors
- Perception of insider selling pressure, especially following recent transactions.
- Potential downward price pressure if the full 21,000 shares are sold rapidly.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-003530 |
| Document: 0001950047-26-003530-index.html | 0001950047-26-003530 |
| Document: 0001950047-26-003530.txt | 0001950047-26-003530 |
Track record
40 reports on ORKA
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers